ArticleDrugs & aging2025
Patterns and Characteristics of Gabapentin Use Among Medicare Beneficiaries.
Article in Drugs & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGabapentin is increasingly prescribed to older adults, yet prescribing patterns and characteristics of gabapentin initiators remain unclear.
methodsWe conducted a retrospective cohort study of gabapentin initiators using a random sample of age-eligible fee-for-service Medicare beneficiaries (2012-2021) enrolled in Parts A, B, and D. Gabapentin initiators were identified from pharmacy claims. We required 180 days of continuous enrollment (washout period) prior to initiation (index date) for inclusion. We analyzed demographics, healthcare utilization within 3 months of initiation, chronic conditions, medication history during washout period, and patterns of gabapentin use. Subgroup analyses compared initiators by duration of continuous gabapentin use (≤ 90 days, 91-180 days, and > 180 days).
resultsThe prevalence of gabapentin prescriptions increased over time, from 6.7% (2013) to 10.2% (2021). Among 247,612 gabapentin initiators (mean age 76.1 years, 61.5% female, 89.2% white), chronic pain (32.6%) was the most commonly documented condition, while epilepsy and postherpetic neuralgia, the approved indications for gabapentin, were documented in fewer than 0.5% of initiators. Among initiators, 38.9% had prior opioid use, and 13.2% were co-prescribed gabapentin and opioids at initiation. About 30% had a history of antidepressant use, predominantly selective serotonin reuptake inhibitors (17.2%). Subgroup analyses showed similar demographics and prescription patterns across subgroups. However, gabapentin initiators with > 180 days continuous use had more neuropathic pain and chronic condition diagnoses documented, fewer opioid co-prescriptions at index, and lower hospitalization rates.
conclusionsGabapentin was frequently prescribed, apparently off-label, in older adults with a high burden of chronic pain and comorbidities; initiators often had co-prescriptions of gabapentin with opioids. Future research is needed to investigate factors associated with extended gabapentin use (> 180 days) and its appropriateness in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.